Clinical Trials Browser

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Hemostatic Disorders, Neoplasms, Plasma Cell

NCT04879043 2024-07-24

Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma

Phase 1/2 Recruiting

78 enrolled

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT06132711 2023-11-15

CAR-T

Phase 1/2 Recruiting

20 enrolled

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT05573802 2023-10-24

A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma

Phase 1/2 Recruiting

36 enrolled

Plasma cell

Blood Protein Disorders, Corneal Diseases, Hematologic Diseases, Multiple Myeloma, Neoplasms, Paraproteinemias, Neoplasms, Plasma Cell

Clinical Trials

Ph I/II Trial of Cord Blood-derived NK Cells With NY-ESO-1 TCR/IL-15 for R/R Myeloma

Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM

Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell Disorders

BAH2573

BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease

a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease

BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma

Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma

CAR-T

A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma